LOVELAND, Colo., Dec. 14 Heska Corporation (Nasdaq: HSKA; "Heska" or the "Company"), a leading provider of veterinary diagnostic and specialty products, today announced the first customer installation of the Company's new DRI-CHEMŪ 7000 Veterinary Chemistry Analyzer (the "DRI-CHEMŪ 7000").
Customers receiving these analyzers have invested in the fastest multi-patient clinical chemistry analyzer available to the veterinary in-clinic market. The DRI-CHEMŪ 7000 analyzer provides the same testing flexibility of the DRI-CHEMŪ 4000 Veterinary Chemistry Analyzer plus additional advantages such as multiple-patient staging, auto-dilution and a new "STAT" sample feature which provides emergency sample flexibility in critical cases.
"We are pleased to deliver another choice for advanced chemistry analyzers to the veterinary market and believe this latest addition will continue to support our customers' needs for fast and accurate chemistry results," said Robert Grieve, Heska's Chairman and Chief Executive Officer. "Heska's dedicated pursuit to bringing the most advanced diagnostics to the veterinary industry is resolute."
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
This announcement contains forward-looking statements regarding Heska's future operations. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that these statements are based on current plans, which may not be fulfilled as expected and may not have the positive impact even if fulfilled as expected. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties surrounding recently launched products, including Heska's ability to successfully commercialize such products; risks regarding Heska's ability to successfully market, sell and distribute its products in an economically sustainable manner; competition, including uncertainties regarding the impact of new products competitors have recently launched or may launch in the future; risks regarding Heska's reliance on third-party suppliers, which is substantial and could have significant negative consequences if Heska were to lose exclusive rights or access to a product due to a supplier decision or for other reasons; uncertainties related to the loss of access to products from Abbott Point of Care Inc. after November 1, 2009, which represent approximately 18% of Heska's revenue for the year ended September 30, 2009; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and whom may be large Heska customers; uncertainties regarding Heska's ability to generate profits and positive cash flow in future periods; uncertainties related to Heska's ability to maintain its listing on the Nasdaq Capital Market; risks related to Heska's reliance on third parties to properly and timely complete certain research and development activities; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.
SOURCE Heska Corporation